MOMasayuki Okuno

Masayuki Okuno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masayuki Okuno has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Treatment Interval as a Prognostic Marker in Patients Undergoing Repeated Curative‐Intent Local Treatment for Recurrent Hepatocellular Carcinoma

    by Katsunori Sakamoto, Tomoaki Yoh, Satoshi Nomura, Kentaro Kadono, Hidenobu Kojima, Asahi Sato, Shoichi Kageyama, Hirofumi Hirao, Takahiro Nishio, Shinya Okumura, et al.

    Purpose: This study aimed to investigate the prognostic impact of the interval between curative‐intent local treatments in patients undergoing repeated therapies for recurrent hepatocellular carcinoma after hepatectomy. Methods: The present retrospective cohort study included 890 patients who underwent hepatectomy for HCC at our hospital between 2001 and 2020. Overall survival (OS) was evaluated from the time of each curative‐intent local treatment, according to the number of treatments received and the intervals between consecutive curative‐intent treatments for intrahepatic recurrence, up to the fourth session. Results: During follow‐up, 625 patients (65.9%) developed intrahepatic recurrence. The median intervals gradually shortened to 24.9, 14.5, 12.4, and 12.8 months from hepatectomy to the first curative treatment, from the first to the second, from the second to the third, and from the third to the fourth treatments, respectively. For the first and second curative treatments, the pretreatment interval was not an independent predictor of OS. At the third curative treatment, an interval < 18.6 months between the second and third curative treatments independently predicted poorer OS (hazard ratio [HR] 2.280 and 95% confidence interval [CI] 1.046–4.967). For the fourth curative treatment, an interval < 14.1 months between the third and fourth treatments was an independent adverse prognostic factor (HR 4.961, 95% CI 1.607–15.319). The prognostic impact of treatment interval was more pronounced in patients who underwent ≥ 3 treatments, with a significant interaction compared with < 3 treatments. Conclusions: Among patients who remained eligible for repeated curative‐intent local treatment, a shortened interval between treatments in late‐phase recurrence was an independent predictor of poor prognosis.

  • Open Access

    Vessel co-option negatively affects survival in patients with advanced hepatocellular carcinoma

    by Masayuki Okuno, Yutaro Hori, Masato Komatsu, Hiroto Nishino, Yusuke Kawabata, Tomoaki Yoh, Takahiro Nishio, Satoshi Ogiso, Ikuo Nakamura, Takamichi Ishii, et al.

  • Open Access

    Spatial and functional polarization of cancer-associated fibroblasts with CXCR4-mediated immune modulation in hepatocellular carcinoma

    by Daichi Nakamura, Takahiro Nishio, Yo Oguma, Kojiro Taura, Yukinori Koyama, Mengyang Zhan, Yoshihiko Kurata, Keisuke Okura, Tomoaki Yoh, Hiroto Nishino, et al.

    Background: Cancer-associated fibroblasts (CAFs) represent a predominant cell population in the tumor microenvironment (TME) of hepatocellular carcinoma (HCC). How the spatial distribution of CAF subtypes relates to immune modulation within the TME remains incompletely understood. This study aimed to characterize the spatial organization of CAF subtypes in HCC and to explore their potential associations with immune contexture. Methods: Spatial transcriptomic analysis was performed on 6 HCC cases to identify CAF-enriched clusters and their spatial localization. Immunohistochemical analyses were conducted on 132 HCC sections to examine the relationship between CAF-related features, immune cell distribution, and clinical outcomes. Results: Spatial transcriptomic analysis identified distinct CAF sub-clusters, including myofibroblastic CAFs (myCAFs), which were predominantly localized within tumor regions and enriched for extracellular matrix–related gene expression; inflammatory CAFs (iCAFs), which were preferentially localized within tumor septa and associated with inflammatory signaling; and antigen-presenting CAFs (apCAFs), which were enriched in the peritumoral zone and exhibited gene expression patterns suggestive of immune-related functions. Interactome analysis suggested that apCAFs in the peritumoral region showed transcriptional patterns consistent with CXCL12–CXCR4–related interactions with CD8 + T cells accumulating at the tumor periphery. The enrichment of apCAFs on the outer side of tumor septa was associated with reduced intra-tumoral CD8 + T-cell infiltration and poorer prognosis, suggesting a link between apCAF distribution and an immune-excluded TME. Conclusions: Spatial transcriptomic profiling suggests that CAFs exhibit functional and spatial polarization in the TME of HCC. ApCAFs are associated with CXCR4-related immune exclusion at the tumor–stroma interface and may represent a stromal component relevant to immune modulation. These findings provide a framework for CAF–immune interactions and serve as a basis for future functional studies targeting the CXCL12–CXCR4 axis.


  • Open Access

    Response Rate Correlates with the Conversion Rate in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic or Hepatic Artery Infusion Chemotherapy: A Systematic Review

    by Masayuki Okuno, Hiroto Nishino, Keisuke Okura, Takamichi Ishii, Hiroki Hashida, Etsuro Hatano

    Introduction: The appropriate regimen for induction therapy with the intent of conversion therapy for advanced hepatocellular carcinoma (HCC) is unknown. This study aimed to evaluate whether the overall response rate (ORR) of chemotherapy correlates with the conversion rate. Methods: The studies of phase 2/3 trials of systemic or hepatic artery infusion chemotherapy (HAIC) for patients with advanced HCC were searched. Spearman’s correlation coefficient was calculated to measure the strength of the relationship between the conversion rate and the ORR. Results: A total of 42 patient groups from 32 trials were included in the analysis. The ORR and conversion rates in a total of 3,516 patients were 24.7% and 8.3%, respectively. The analysis of only the patient groups treated with 1st-line immune checkpoint inhibitors, tyrosine kinase inhibitors or HAIC revealed a strong correlation between the ORR and the conversion rate (ρ = 0.647, p = 0.0003). In addition, strong correlations between the ORR and median progression-free survival (PFS)/overall survival (OS) were observed (ρ = 0.772, p < 0.0001 and ρ = 0.754, p < 0.0001, respectively). Conclusion: Because of the strong correlations of the ORR with the conversion rate and PFS/OS, regimens with high ORRs may be used for patients with advanced HCC who are potential candidates for conversion therapy.

  • Open Access

    Activated hepatic stellate cells are required for Hippo–YAP activation and functional liver regeneration following portal vein ligation in mice

    by Keisuke Okura, Yukinori Koyama, Takahiro Nishio, Yoshihiko Kurata, Daichi Nakamura, Hiroto Nishino, Tomoaki Yoh, Masayuki Okuno, Keiko Iwaisako, Etsuro Hatano


  • Open Access

    Clarifying Treatment Compliance and Future Directions in Perioperative Chemotherapy for Resectable Colorectal Liver Metastases

    by Masayuki Okuno, Hiroto Nishino, Takamichi Ishii, Etsuro Hatano

  • Open Access

    A classification model for resectability in hepatocellular carcinoma patients

    by Ikuo Nakamura, Tomoaki Yoh, Takashi Nishimura, Masayuki Okuno, Tomohiro Okamoto, Hideaki Sueoka, Kenjiro Iida, Masaharu Tada, Takamichi Ishii, Satoru Seo, et al.

    Aim: Some patients undergoing liver resection for hepatocellular carcinoma (HCC) have poor outcomes. Therefore, we aimed to propose a new resectability classification for patients with HCC.Methods: We classified patients into three categories: resectable (R), borderline resectable (BR), and unresectable (UR). Patients (n = 409) who underwent hepatectomy for HCC were assigned to the non‐UR (R and BR classes combined; n = 285) and UR‐HCC classes (n = 68; training cohort). Patient characteristics in the BR‐HCC and R‐HCC groups were compared. The new criteria were tested in a validation cohort (n = 295).Results: Of the 285 patients, 229 and 56 were classified into the R‐ and BR‐HCC classes, respectively, using macrovascular invasion, tumor size, and future liver remnant/modified albumin‐bilirubin scores. Patients with BR‐HCC demonstrated significantly worse progression‐free and overall survival (p < 0.0001 and p < 0.0001, respectively) than patients with R‐HCC in the training cohort. Similar results were observed in the validation cohort. Multivariate analysis of the non‐UR‐HCC group in the training cohort revealed that the tumor number and BR‐HCC were independent predictive factors for poor overall survival.Conclusions: This classification can help select patients with BR‐HCC for preoperative treatment before considering surgery.


  • A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response

    by Masayuki Okuno, Hideko Ohama, Ikuo Nakamura, Makoto Yoshida, Daisuke Shirai, Takahito Hirai, Hiroaki Fuji, Ami Kurimoto, Tomohiro Okamoto, Hideaki Sueoka, et al.

    Here, we present a patient with hepatocellular carcinoma complicated by tumor thrombosis into the main portal trunk and perihepatic lymph node metastases who was treated with atezolizumab plus bevacizumab. Shrinkage of the main tumor, portal vein thrombosis, and lymph node metastases were achieved; therefore, hepatectomy with lymphadenectomy could be performed. Final pathology indicated a complete pathological response in the main tumor, portal vein thrombosis, and perihepatic lymph nodes. The patient is currently alive with no evidence of recurrence on radiological assessment at 3 months after surgery.


  • Open Access

    Surgical intervention after lenvatinib treatment in patients with advanced hepatocellular carcinoma

    by Masayuki Okuno, Etsuro Hatano, Masaharu Tada, Takashi Nishimura, Tomohiro Okamoto, Hideaki Sueoka, Kenjiro Iida, Ikuo Nakamura, Hiroko Iijima, Seiko Hirono

    Background Survival efficacy and prognostic factors in patients with advanced hepatocellular carcinoma (HCC) who underwent surgical intervention after lenvatinib treatment is not well-understood.Methods Patients with advanced HCC who had lenvatinib treatment were retrospectively analyzed.Results Of 70 patients who were treated with lenvatinib, 14 patients underwent surgical intervention after lenvatinib treatment for 4–28 weeks. PFS was significantly longer in patients with surgical intervention than in patients with non-surgical treatment (median, 8.6 vs. 5.1 months, p = 0.019). Non-significant longer OS was also observed in patients with surgical intervention compared to patients with non-surgical treatment (median, unreached vs. 21.0 months, p = 0.206). In patients who underwent surgical intervention, 2 patients had a PR, and 12 had SD according to RECIST ver. 1.1 criteria. The serum AFP level was significantly lower after lenvatinib treatment than before lenvatinib treatment (median, 19.2 vs. 196.5 ng/mL, p = 0.0081). Eleven patients underwent curative surgery with a 14% major postoperative complication (Clavien‒Dindo ≥ IIIa) rate. Patients who exhibited decreases in AFP levels or were within the normal range of AFP levels during lenvatinib treatment had significantly longer PFS (median, 8.6 vs. 3.0 months, p = 0.0009) and OS (median, unreached vs. 12.4 months, p = 0.012) than patients who had AFP levels beyond the normal range that did not decrease during lenvatinib treatment.Conclusions Surgical intervention after lenvatinib treatment for advanced HCC was associated with longer PFS. Patients exhibiting decreases in AFP levels or were within the normal limit of AFP levels may be good candidates for surgical intervention after lenvatinib treatment for advanced HCC.